Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENOGLIDE vs BUMETANIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma, reduces hepatic production of VLDL, and increases HDL cholesterol.
Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Primary hypercholesterolemia,Mixed dyslipidemia,Severe hypertriglyceridemia
Edema associated with congestive heart failure, hepatic cirrhosis, and renal disease,Treatment of hypertension (off-label)
160 mg orally once daily, taken with or without food.
0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.
The terminal elimination half-life of fenofibric acid is approximately 20 hours (range 15-25 hours). This long half-life allows once-daily dosing. Steady-state is reached within approximately 5 days.
Terminal elimination half-life is approximately 1-1.5 hours in healthy adults; prolonged to 1.5-3 hours in renal impairment.
Hepatic metabolism via glucuronidation; minor CYP450 involvement (CYP3A4).
Primarily metabolized by the liver via cytochrome P450 (CYP) enzymes, with approximately 50% excreted unchanged in urine.
Fenoglide (fenofibrate) is primarily excreted in urine as fenofibric acid and its glucuronide conjugate, accounting for approximately 60-70% of the dose. About 20-25% is eliminated in feces via biliary excretion. Renal excretion is the major route.
Primarily renal (approximately 80% as unchanged drug), with minimal biliary/fecal excretion (about 10-20%).
Fenofibric acid is extensively bound to plasma proteins, primarily albumin, with a binding rate greater than 99%.
Approximately 95% bound, primarily to albumin.
The apparent volume of distribution (Vd) of fenofibric acid is approximately 0.9 L/kg. This suggests distribution into total body water, with some tissue binding.
0.15-0.25 L/kg; indicates limited extravascular distribution, consistent with high protein binding.
The absolute oral bioavailability of fenofibric acid from fenofibrate tablets is approximately 90% under fed conditions. Administration with food increases absorption by up to 35% compared to fasting.
Oral: approximately 80-100% (mean ~90%), with a first-pass effect of about 10-20%.
No dose adjustment required for mild to moderate renal impairment (e GFR >30 m L/min/1.73 m2). Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m2) or dialysis.
No specific dose adjustment for GFR >20 m L/min. For GFR 10-20 m L/min: use with caution, dose every 12-24 hours. For GFR <10 m L/min: not recommended due to lack of efficacy.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use caution in moderate impairment (Child-Pugh class B); consider dose reduction.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Not approved for use in pediatric patients under 18 years of age.
IV/IM/PO: 0.015-0.1 mg/kg/dose every 6-24 hours; max 10 mg/day. For neonates: 0.01-0.05 mg/kg/dose every 12-24 hours.
No specific dose adjustment; monitor renal function due to age-related decline.
Start at 0.5 mg once daily; titrate cautiously due to increased sensitivity and risk of electrolyte imbalance and volume depletion.
No FDA black box warning.
Bumetanide is a potent diuretic that can lead to profound diuresis with water and electrolyte depletion. Close medical supervision and dose titration are required. Excessive doses can lead to hypovolemia, dehydration, and circulatory collapse.
Hepatotoxicity: rare but severe; monitor liver enzymes.,Rhabdomyolysis: risk increased with renal impairment, hypothyroidism, statins.,Renal function: dose adjustment needed in mild-moderate impairment; contraindicated in severe renal disease.,Cholelithiasis: fenofibrate increases cholesterol excretion into bile.,Pancreatitis: associated with severe hypertriglyceridemia; monitor triglycerides.,Venous thromboembolism: increased risk with fenofibrate.
Monitor fluid and electrolyte balance closely,Risk of ototoxicity, especially at high doses or with rapid infusion,May cause hyperuricemia and precipitate gout attacks,Can increase risk of digitalis toxicity due to hypokalemia
Severe renal impairment (e GFR <30 m L/min/1.73m²),Active liver disease including primary biliary cirrhosis,Known hypersensitivity to fenofibrate or excipients,Gallbladder disease,Nursing mothers
Anuria,Severe electrolyte depletion,Hepatic coma or pre-coma,Hypersensitivity to bumetanide or sulfonamides
Take with food to enhance absorption. Avoid high-fat meals immediately before or after dose. Grapefruit juice may increase fenofibrate exposure (moderate interaction, monitor). Statin co-administration: avoid large amounts of grapefruit juice.
No specific food restrictions, but limit salt intake to help control edema and hypertension. Avoid excessive intake of black licorice (can worsen hypokalemia). Grapefruit juice may not significantly interact, but caution with any electrolyte-altering foods. Maintain adequate fluid intake unless fluid restriction is advised by your doctor. Foods high in potassium (bananas, oranges, spinach) may be recommended if hypokalemia occurs; consult provider for individual needs.
First trimester: No adequate studies; animal data show no major malformations at clinically relevant doses. Second and third trimesters: Associated with adverse maternal and fetal outcomes (e.g., preterm birth, low birth weight) due to β-receptor agonist effects. Avoid use during pregnancy.
Bumetanide crosses the placenta. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Risk of electrolyte imbalances and hypovolemia in the fetus; possible oligohydramnios. Avoid use during pregnancy unless benefits outweigh risks.
Excreted in breast milk; M/P ratio unknown. Potential for neonatal β-receptor stimulation. Caution advised; manufacturer recommends discontinuing breastfeeding or drug.
Bumetanide is excreted into human milk in small amounts (M/P ratio not determined). Due to potential for diuresis in the infant, use with caution, especially in neonates. Consider alternative agents with more safety data.
No established dose adjustments for pregnancy; use only if potential benefit outweighs risk. Consideration of lower doses due to altered pharmacokinetics (increased clearance, decreased plasma concentration).
Pregnancy may increase volume of distribution and renal clearance, potentially requiring higher doses. However, starting dose is generally unchanged; titration based on response and tolerability. Monitor for hypokalemia and hypovolemia.
Fenofibrate is a fibric acid derivative used primarily for hypertriglyceridemia and mixed dyslipidemia. It activates PPAR-alpha, increasing lipoprotein lipase and reducing apolipoprotein C-III. Monitor renal function; dose adjustment required for Cr Cl 30-60 m L/min. Contraindicated in severe renal impairment (Cr Cl <30) and active liver disease. Can increase serum creatinine, but this is often reversible. Co-administration with statins increases risk of myopathy, especially in elderly or renal impairment. May increase homocysteine levels; monitor if at risk for thrombosis.
Bumetanide is a potent loop diuretic with rapid onset and short duration. Oral bioavailability is ~80% with minimal first-pass metabolism. Onset of diuresis within 30-60 minutes, peak at 1-2 hours, duration 4-6 hours. For acute pulmonary edema, intravenous bumetanide can be given 0.5-1 mg; onset within minutes. Monitor electrolytes especially potassium, magnesium, and calcium due to increased excretion. May cause ototoxicity, especially with rapid IV administration or concurrent aminoglycosides. Use with caution in sulfonamide allergy (cross-sensitivity). In renal impairment, bumetanide may be less effective due to reduced tubular secretion; higher doses may be needed. Combine with thiazides for sequential nephron blockade in resistant edema.
Take with food to improve absorption.,Avoid alcohol as it may worsen triglyceride levels.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Do not stop medication without consulting your doctor, even if you feel well.,Keep all appointments for blood tests to monitor liver function and lipid levels.
Take bumetanide exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Do not skip doses or double up on missed doses; if you miss a dose, take it as soon as you remember unless it is almost time for the next dose.,This medication can cause dehydration and electrolyte imbalances; notify your doctor if you experience excessive thirst, dry mouth, weakness, muscle cramps, or irregular heartbeat.,Avoid alcohol and over-the-counter medications, especially NSAIDs (ibuprofen, naproxen) unless approved by your doctor, as they may reduce bumetanide's effectiveness and increase kidney risk.,Stand up slowly from sitting or lying to prevent dizziness from low blood pressure.,Monitor your weight daily and report rapid weight gain or loss to your healthcare provider.
No interactions on record
"Concurrent use of bumetanide, a loop diuretic, and allopurinol, a xanthine oxidase inhibitor, may increase the risk of allopurinol hypersensitivity reactions, including Stevens-Johnson syndrome and acute gout flares. This interaction is thought to result from bumetanide-induced volume depletion and reduced renal clearance of oxypurinol, the active metabolite of allopurinol, leading to elevated serum oxypurinol levels and enhanced toxicity. Clinically, patients may present with rash, fever, eosinophilia, or acute gouty arthritis, particularly in those with renal impairment."
"Fenbufen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits renal prostaglandin synthesis, which can reduce the efficacy of loop diuretics like bumetanide by blunting the diuretic-induced increase in renal blood flow and sodium excretion. This pharmacodynamic antagonism may result in diminished diuresis and natriuresis, potentially exacerbating fluid overload in patients with heart failure or hypertension. Clinically, this interaction may lead to suboptimal blood pressure control or worsening edema if the combination is used without dose adjustment."
"Concurrent administration of apomorphine, a dopamine agonist used for Parkinson's disease, with bumetanide, a loop diuretic, may lead to an increased risk of adverse effects, particularly hypotension and syncope. Apomorphine is known to cause orthostatic hypotension due to its vasodilatory and dopaminergic effects, which can be potentiated by bumetanide-induced volume depletion and electrolyte disturbances. This interaction can result in profound blood pressure drops, dizziness, and potential falls, especially in elderly patients or those with already compromised cardiovascular status."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENOGLIDE vs BUMETANIDE, answered by our medical review team.
FENOGLIDE is a Antilipemic that works by Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma, reduces hepatic production of VLDL, and increases HDL cholesterol.. BUMETANIDE is a Loop Diuretic that works by Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENOGLIDE and BUMETANIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENOGLIDE is: 160 mg orally once daily, taken with or without food.. The standard adult dose of BUMETANIDE is: 0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FENOGLIDE and BUMETANIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FENOGLIDE is classified as Category C. First trimester: No adequate studies; animal data show no major malformations at clinically relevant doses. Second and third trimesters: Associated with adverse maternal and fetal . BUMETANIDE is classified as Category A/B. Bumetanide crosses the placenta. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Risk o. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.